title: Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study.
abstract: Inosine-pranobex (methisoprinol, isoprinosine; INPX) is the p-acetamidobenzoic salt of N,N-dimethylamino-2-propanol and inosine in a 3:1 molar ratio. In early studies, INPX was found to partially inhibit human immunodeficiency virus (HIV) and to increase the immunocompetence of HIV-infected subjects in vitro. We report the results of a randomised, multicentric clinical trial carried out on 553 HIV+ patients. 261 individuals were treated with INPX (two 500 mg tablets every 6 h for 3 months) and the remaining 292 constituted the untreated control group. INPX treatment was associated with a slightly improved clinical condition or with a trend in that direction, as compared to the untreated group. A preservation of the CD4/CD8 cell ratio values, a decrease in the CD8+ cells and an increase in the Leu 2-7+ cell number better than in the untreated individuals was also observed in the patients taking INPX. No serious or adverse effects of INPX have been observed.
authors: Insegnamento Malattie Infettive, Università, L'Aquila, Italia.
authors: C
authors: C
authors: De Simone
authors: F
authors: F
authors: Albertini
authors: M
authors: M
authors: Almaviva
authors: G
authors: G
authors: Angarano
authors: F
authors: F
authors: Chiodo
authors: P
authors: P
authors: Costigliola
authors: S
authors: S
authors: Delia
authors: A
authors: A
authors: Ferlini
authors: F
authors: F
authors: Gritti
authors: G
authors: G
authors: Mazzarello
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008297:Male; D015337:Multicenter Studies as Topic; D011897:Random Allocation
chemical_list: D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007288:Inosine; D007542:Inosine Pranobex